Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

Remember that the DMT Phase 1 was to determine "sub psychedelic dose levels". AGN had also paid for specific neuro marker tests that should help prove ' MOU/ proof of concept' for the upcoming Phase 2 CT, which is/has been planned now.
I sure hope that phase 2 data from the Ifenprodil CT will help find a buyer as that data is as strong as any drug's for IPF/CC. This should be enough to finance the next steps for DMT, possible even the whols Phase 2 CT. I bet this is 'of course' the main focus for Mr Monroue.
The peer data from DMT should also be released soon.
As 60% owners of AGN-Neuro we are financing all this and at the least will see proportional benefits, maybe even the dividends you mentioned. JMHO.
...GLTA...